Ascendis Pharma Gets Positive European Opinion for Achondroplasia Drug
Ascendis Pharma said it received a positive European regulatory opinion for its once-weekly treatment for children with achondroplasia. The shares closed down 0.6%.
Ascendis Pharma said it received a positive European regulatory opinion for its once-weekly treatment for children with achondroplasia. The shares closed down 0.6%.